Eli Lilly has been awarded approval from the FDA for its Baqsimi nasal powder in the treatment of severe hypoglycaemia, it has emerged, marking the authorisation of the first glucagon therapy in this indication in the US that can be administered without an injection.
Differing from the traditional injectable glucagon treatments which have been approved for decades, the therapy takes the form of a powder which is administered nasally via a single-use dispenser.
![[column] Toekomst tijdschriften glanst als nooit tevoren](https://www.pharmamarketeer.nl/wp-content/uploads/2024/12/happy-couple-in-t-shirts-reading-newspaper-while-h-2024-11-10-00-13-23-utc-1-80x60.jpg)
![[column] MarketingAffairs 17: Marketing als oplossing](https://www.pharmamarketeer.nl/wp-content/uploads/2024/12/asian-seo-manager-writing-on-glass-with-illustrati-2024-11-17-23-11-51-utc-1-80x60.jpg)
